MarketPR
A securities plaintiff firm has put Ionis Pharmaceuticals, Inc. Pomerantz LLP disclosed on July 16, 2026, that it is investigating claims on behalf of investors in the NASDAQ-listed company.
The firm named Danielle Peyton as the point of contact, reachable at newaction@pomlaw.com or 646-581-9980, ext. What the disclosure contains The announcement was issued from New York via PRNewswire on July 16, 2026.
Pomerantz identified Ionis Pharmaceuticals by its full legal name and NASDAQ ticker. The firm offered no information about what triggered the inquiry, the nature of the claims, or the time period at issue.
The disclosure is limited to the fact of the investigation and contact details for affected investors. What to watch The next material development would be a formal complaint, if Pomerantz elects to file one.
Keep reading